Carolinas Wealth Consulting’s Myriad Genetics MYGN Stock Holding History

Carolinas Wealth Consulting’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-115	Closed	-$1.67K	–	1104
2022 Q4	$1.67K	Sell	115 -5	-4%	-$93	﹤0.01%	830
2022 Q3	$2K	Hold	120	–	–	﹤0.01%	769
2022 Q2	$2K	Hold	120	–	–	﹤0.01%	771
2022 Q1	$3K	Hold	120	–	–	﹤0.01%	766
2021 Q4	$3K	Buy	120 +1	+0.8%	+$29	﹤0.01%	780
2021 Q3	$4K	Hold	119	–	–	﹤0.01%	708
2021 Q2	$4K	Sell	119 -35	-23%	-$1.01K	﹤0.01%	734
2021 Q1	$5K	Buy	154 +43	+39%	+$1.22K	﹤0.01%	718
2020 Q4	$2K	Sell	111 -20	-15%	-$323	﹤0.01%	749
2020 Q3	$2K	Buy	+131	New	+$1.66K	﹤0.01%	722

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Carolinas Wealth Consulting's MYGN Position: Q1 2023 in Review

Carolinas Wealth Consulting sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 115 shares — an estimated $1.67K sold.

Carolinas Wealth Consulting first reported a position in MYGN in Q3 2020 and held it in 10 quarters. The position peaked at $5K in Q1 2021. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

Carolinas Wealth Consulting reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
Carolinas Wealth Consulting sold 115 Myriad Genetics shares in Q1 2023, an estimated $1.67K.
Carolinas Wealth Consulting first reported a position in Myriad Genetics in Q3 2020 and held it in 10 quarters.
Carolinas Wealth Consulting's Myriad Genetics position peaked at $5K in Q1 2021.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Carolinas Wealth Consulting's 13F filing for Q1 2023, filed 16 May 2023.